[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100641056":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":29,"responsibleParty":45,"collaborators":10,"id":47,"slug":10,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":10,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":10,"enrollmentInfo":55,"targetDuration":10,"studyType":58,"phases":10,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":32,"whyStopped":10,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Barts & The London NHS Trust","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"AF induced Cardiomyopathy (Cases)",null,"Patients with LVSD during rate-controlled, persistent AF who improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.",{"label":13,"type":10,"description":14,"interventionNames":10},"AF-preserved EF (Negative controls)","Patients without LVSD during rate-controlled, persistent AF",{"label":16,"type":10,"description":17,"interventionNames":10},"AF\u002FHF non-responders (Positive controls)","Patients with LVSD during rate-controlled, persistent AF who do not significantly improve their LVEF after sustained SR is achieved using catheter ablation or cardioversion.",[19],{"name":20,"affiliation":21,"role":22},"Shohreh Honarbakhsh, MBBS, PhD","Queen Mary University of London","PRINCIPAL_INVESTIGATOR",[24],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Nikhil Ahluwalia, MBBS, PhD","CONTACT","+44(0) 20 3465 5398","nikhil.ahluwalia@nhs.net",[30],{"facility":31,"status":32,"city":33,"state":10,"zip":34,"country":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"St Bartholomew's Hospital, Barts Health NHS Trust","RECRUITING","London","EC1A 7BE","United Kingdom",{"type":37,"coordinates":38},"Point",[39,40],-0.12574,51.50853,{"lat":40,"lon":39},[43],{"name":44,"role":26,"phone":10,"phoneExt":10,"email":28},"Nikhil Ahluwalia",{"type":46,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100641056",false,"NCT07574697","AIC Genotyping Study","Genetic Susceptibility to AF-Induced Cardiomyopathy","INCLUSION:\n\nAIC (Cases):\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≤40% during rate-controlled (resting HR \\\u003C100bpm, mean HR on 24-hour Holter \\\u003C100bpm) AF prior to index catheter ablation or cardioversion\n* LVEF normalisation (LVEF ≥55%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (\\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation), and with no new introduction of any new or increased dose of heart failure guideline-directed medical therapy (GDMT) (renin-angiotensin-aldosterone system inhibitors (RAASi), Sodium Glucose Co-transporter 2 (SLGT2) inhibitors, increased dose of beta-blocker (BB), mineralocorticoid receptor antagonist (MRA))\n\nAF-pEF (Negative controls):\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≥55% during rate-controlled (resting HR \\\u003C100bpm) AF. AIC-genotyping study, v1.7, 27.01.26 Page 13 of 28\n\nAF\u002FHF non-responders (Positive controls)\n\n* Age ≥18\n* Persistent AF before index catheter ablation or cardioversion\n* LVEF ≤40% during rate-controlled (resting HR \\\u003C100bpm) AF before index catheter ablation or cardioversion.\n* Persistent LVSD (LVEF ≤40%) in SR, post-catheter ablation or cardioversion (≥3 months post-catheter ablation or cardioversion), no AF (\\>30 seconds of continuous AF) detected outside blanking period (8 weeks post-catheter ablation) and with no change in heart failure GDMT (RAASi, SGLT2 inhibitors, increased dose of BB, MRA).\n\nEXCLUSION:\n\nAIC (Cases).\n\n* No alternative cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek\n* Any history of cardiotoxic chemotherapy\n\nAF-pEF (Negative controls)\n\n* No known cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek.\n* Any history of cardiotoxic chemotherapy.\n\nAF\u002FHF non-responders (Positive controls)\n\n* No alternative cause for LVSD (ischemic cardiomyopathy\u002Fnon-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy).\n* Any pregnancy during AF or in the 12 months preceding LVSD onset.\n* Alcohol intake \\>21 units\u002Fweek.\n* Any history of cardiotoxic chemotherapy.","ALL","18 Years",{"count":56,"type":57},299,"ESTIMATED","OBSERVATIONAL","To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive\u002Fnegative controls",[61,62,63],"Cardiomyopathy","Atrial Fibrillation (AF)","Genetic",[65,66,67],"prospective","case-controlled","genetics","2026-05-05",{"date":70,"type":71},"2026-05-08","ACTUAL",{"date":73,"type":71},"2026-03-25",{"date":75,"type":57},"2027-05-31",{"name":5,"class":6},1]